Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245583 · ClinicalTrials.gov registry record · Phase 3
Topiramate in the Treatment of Pathological Gambling
A Phase 3 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT00245583 is a Phase 3 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 42 participants.
The verdict
NCT00245583, a Phase 3 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will assess the efficacy of topiramate in the treatment of pathological gambling. Pathological gambling (PG) is a debilitating disorder, generally leading to severe personal, familial, financial, social, and occupational impairments. In PG, the patient experiences a progressive inability to resist impulses to gamble, and gambling significantly disrupt the patient's functioning in the personal, familial, and/or vocational spheres. Topiramate has shown preliminary evidence of efficacy in some impulse control disorders.
Interventions
- DRUG Placebo
- DRUG Topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245583
The ClinicalTrials.gov registry entry for NCT00245583 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00245583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245583 about?
NCT00245583 is a clinical study titled "Topiramate in the Treatment of Pathological Gambling". This study will assess the efficacy of topiramate in the treatment of pathological gambling. Pathological gambling (PG) is a debilitating disorder, generally leading to severe personal, familial, financial, social, and occupational impairments. In PG, the patient experiences a progressive inability ...
What is the current status of trial NCT00245583?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2005-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00245583?
The interventions under investigation include: Placebo (DRUG), Topiramate (DRUG).
Who is sponsoring clinical trial NCT00245583?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.